Immunai, a New York-based biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system, raised $215 million in Series B.
The round was led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, and others, bringing the company’s total funding to $295 million.
The Series B round will be used to bring in more employees and to keep enriching the immunological data set at the company’s disposal.
Round: Series B
Funding Month: October 2021
Lead Investors: Koch Disruptive Technologies
Additional Investors: Talos VC, 8VC, Alexandria Venture Investments, Piedmont, and ICON
Company Website: https://www.immunai.com/
Software Category: Immune profiling platform
About the Company: Founded in December 2018, Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai leverages single-cell technologies to profile cells from a blood sample and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. Immunai’s end-to-end platform is generating the world’s largest knowledge base of high granularity immunological data.